Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breast cancer prevention with fenretinide in young high-risk women
2009-010260-41Phase 3Completed
- Sponsor
- European Institute of Oncology
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fenretinide in breast cancer, Breast carcinoma in situ (BCIS), ductal carcinoma in situ (DCIS) and 3 more (2 arms), sponsored by European Institute of Oncology. Primary endpoint: Incidence of invasive breast cancer and ductal intraepithelial neoplasia. Started Jun 2009; status: completed.
02
Drugs
fenretinide
03
Conditions
breast cancerBreast carcinoma in situ (BCIS)ductal carcinoma in situ (DCIS)lobular neoplasia (LIN)atypical breast hyperplasia
Beyond the preview
Go deeper on 2009-010260-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010260-41.